ESR1 and breast cancer: PTCH1 and CTNNB1 were associated with increased risk specifically in ER+/HER2- breast cancer patients who underwent neoadjuvant chemotherapy, while their hazard ratios were smaller than 1 and/or statistically insignificant in patients with no systemic therapy and patients who underwent endocrine therapy (Table 6).